This roundtable series discusses the option of testing circulating tumor DNA molecular residual disease for personalized care in patients with lung cancer, as discussed by key opinion leaders at virtual live events and interviews.

Using ctDNA Molecular Residual Disease Testing in Lung Cancer

Options for MRD Testing Affect Patient Treatment Plan in Lung Cancer

January 07, 2025

Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.

Liquid Biopsy Techniques Test Lung Cancer MRD Level

December 19, 2024

Luis E. Raez, MD, discusses the current liquid biopsy options for patients with lung cancer through assessing circulating tumor DNA.

Timing of MRD Testing in Lung Cancer Affects Patient Outcomes

November 25, 2024

Oleg Gligich, MD, discusses utilizing circulating tumor DNA to assess patients with lung cancer.